131
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma

, , , &
Pages 1423-1430 | Received 10 Aug 2020, Accepted 27 Oct 2020, Published online: 18 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Guanqun Chao, Zhaojun Wang & Shuo Zhang. (2021) Research on Correlation Between Psychological Factors, Mast Cells, and PAR-2 Signal Pathway in Irritable Bowel syndrome. Journal of Inflammation Research 14, pages 1427-1436.
Read now

Articles from other publishers (6)

Miaomiao Cheng, Qi Xin, Saiyu Ma, Mengyue Ge, Feng Wang, Xiyun Yan & Bing Jiang. (2023) Advances in the Theranostics of Oesophageal Squamous Carcinoma. Advanced Therapeutics 6:7.
Crossref
Nadia Saoudi González, Florian Castet, Elena Élez, Teresa Macarulla & Josep Tabernero. (2022) Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Frontiers in Oncology 12.
Crossref
Xiangyu Chen, Jianyu Wang, Liang Song, Yang Yu, Mo Shi, Wenpeng Jiang, Xiangyan Liu & Xiaopeng He. (2022) Downregulation of fibulin‐4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt‐mTOR signaling pathway . Thoracic Cancer 13:18, pages 2592-2605.
Crossref
Jidong ZhaoMing HeJie LiDan LiYang ZhaoXinhui LiXiangmei ZhangXin ChenYunjiang Liu & Liyan Zhao. (2022) Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer Biotherapy and Radiopharmaceuticals 37:4, pages 324-331.
Crossref
Lei Wang, Huiqiong Han, Zehua Wang, Litong Shi, Mei Yang & Yanru Qin. (2021) Targeting the Microenvironment in Esophageal Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Bangtao Yao, Gang Liu, Bei Wang & Qian Cao. (2021) Acute Hypertensive Retinochoroidopathy Secondary to an Anti-cancer Drug (apatinib): The First Case Report. Frontiers in Medicine 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.